MedPath

Study to Evaluate System Safety and Clinical Performance of the Protecta Implantable Cardioverter Defibrillator (ICD) Plus Cardiac Resynchronization Therapy Defibrillator (CRT-D)

Phase 4
Completed
Conditions
Health Condition 1: null- TachyarrhythmiasHeart FailureVentricular Dysfunction
Registration Number
CTRI/2010/091/000657
Lead Sponsor
India Medtronic Pvt Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
2000
Inclusion Criteria

Patients meeting one of the following criteria can be included in Phase II of the study:

Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device

Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D

Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant

Exclusion Criteria

Patients with a mechanical tricuspid heart valve
Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study
Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients
Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc)
Patients anticipated not being able to complete the study
Patients unwilling to provide written informed consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath